These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31216465)

  • 1. Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.
    Marcar L; Bardhan K; Gheorghiu L; Dinkelborg P; Pfäffle H; Liu Q; Wang M; Piotrowska Z; Sequist LV; Borgmann K; Settleman JE; Engelman JA; Hata AN; Willers H
    Cell Rep; 2019 Jun; 27(12):3422-3432.e4. PubMed ID: 31216465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
    Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
    Leung EL; Fan XX; Wong MP; Jiang ZH; Liu ZQ; Yao XJ; Lu LL; Zhou YL; Yau LF; Tin VP; Liu L
    Antioxid Redox Signal; 2016 Feb; 24(5):263-79. PubMed ID: 26528827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance.
    Weng MS; Chang JH; Hung WY; Yang YC; Chien MH
    J Exp Clin Cancer Res; 2018 Mar; 37(1):61. PubMed ID: 29548337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
    Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
    Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
    Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.
    Rai K; Takigawa N; Ito S; Kashihara H; Ichihara E; Yasuda T; Shimizu K; Tanimoto M; Kiura K
    Mol Cancer Ther; 2011 Sep; 10(9):1720-7. PubMed ID: 21712475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET.
    Oh HN; Lee MH; Kim E; Kwak AW; Yoon G; Cho SS; Liu K; Chae JI; Shim JH
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32070026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
    Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH
    Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
    Wu DW; Chen TC; Huang HS; Lee H
    Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
    Zhang Z; Lian X; Xie W; Quan J; Liao M; Wu Y; Yang ZZ; Wang G
    Sci Rep; 2020 Dec; 10(1):20924. PubMed ID: 33262410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
    Yamaoka T; Ohba M; Arata S; Ohmori T
    J Vis Exp; 2017 Aug; (126):. PubMed ID: 28829429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells.
    Ryu H; Choi HK; Kim HJ; Kim AY; Song JY; Hwang SG; Kim JS; Kim DU; Kim EH; Kim J; Ahn J
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.
    Lee PC; Fang YF; Yamaguchi H; Wang WJ; Chen TC; Hong X; Ke B; Xia W; Wei Y; Zha Z; Wang Y; Kuo HP; Wang CW; Tu CY; Chen CH; Huang WC; Chiang SF; Nie L; Hou J; Chen CT; Huo L; Yang WH; Deng R; Nakai K; Hsu YH; Chang SS; Chiu TJ; Tang J; Zhang R; Wang L; Fang B; Chen T; Wong KK; Hsu JL; Hung MC
    Cancer Cell; 2018 Dec; 34(6):954-969.e4. PubMed ID: 30537515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.